联系客服

300723 深市 一品红


首页 公告 一品红:2022年度财务决算报告

一品红:2022年度财务决算报告

公告日期:2023-04-20

一品红:2022年度财务决算报告 PDF查看PDF原文

                    一品红药业股份有限公司

                    2022 年度财务决算报告

    一、2022 年度财务报表审计情况

    2022 年 12 月 31 日合并财务报表经由广东司农会计师事务所(特殊普通合
 伙)审计,出具了标准无保留意见的审计报告(司农审字[2023]22008200026 号), 审计认为:公司的财务报表在所有重大方面按照企业会计准则的规定编制,公允
 反映了一品红公司 2022年 12月 31日的财务状况以及 2022年度的经营成果和现
 金流量。

    二、2022 年度主要会计数据和财务指标

                                                                      单位:万元

            项目                  2022 年          2021 年        同比增减

营业收入                                      228,019.86          219,921.44            3.68%

归属于上市公司股东的净利润                  29,068.29          30,691.54            -5.29%

扣除非经常性损益的净利润                    22,108.55          18,193.01            21.52%

经营活动产生的现金流量净额                  47,612.23          43,810.06            59.18%

基本每股收益(元/股)                            1.011              1.091            -7.33%

稀释每股收益(元/股)                          0.9560              1.085            11.89%

加权平均净资产收益率                            14.63%            15.23%            -0.6%

                                    2022 年末        2021 年末        同比增减

资产总额                                      409,844.22          372,813.03            9.93%

上市公司股东的净资产                        205,121.05          187,431.17            9.44%

 三、资产负债情况(单位:万元)

      资产          2022 年末      2022 年初        变化        原因说明

流动资产:                  141,132.81          156,359.98        -9.74%

                                                                          主要原因为期末银行
货币资金                      64,559.58          107,502.54      -39.95%  借款较期初减少所

                                                                          致。

                                                                          主要是期末部分自有
交易性金融资产                7,218.88            1,502.70      380.39%  资金短期理财还没有
                                                                          到期所致。

                                                                          主要是因医药制药销
应收款项融资                                                            售规模增加,收取客
                                14,963.12            4,044.69      269.94%  户银行承兑汇票增加
                                                                          所致。


                                                                          主要是报告期末,因
预付款项                      7,354.14            2,917.73      152.05%  公司加大生产,采购
                                                                          相关原材料所致。

其他应收款                                                                主要是支付供应商保
                                1,239.63            2,716.20      -54.36%  证逐步减少所致。

                                                                          主要是报告期末,因
存货                          17,802.49          11,497.07      54.84%  公司加大生产,采购
                                                                          相关原材料所致。

                                                                          主要是待抵扣增值税
其他流动资产                                                            进项按政策申请退
                                3,182.77            5,884.52      -45.91%  税,因此余额下降所
                                                                          致。

非流动资产:                267,141.73          214,081.50      24.79%

                                                                          主要是生产基地、研
固定资产                      70,646.19          15,870.39      345.14%  发中心建成投产,在
                                                                          建工程转固所致。

其他非流动资产                                                          主要是预付资产购置
                                3,227.23          14,094.47      -77.10%  减少所致。

资产总计                    408,345.19          370,441.48      10.23%

负债及所有者权益

流动负债:                  141,203.45          156,359.98        -9.69%

短期借款                                                                  主要是期末按归还银
                              55,000.00          85,166.34      -35.42%  行借款所致。

                                                                          主要是销售增加,对
应付账款                      6,923.40            4,065.29      70.31%  应的原料采购增加所
                                                                          致。

                                                                          主要是期末收到合同
合同负债                                                                  款项,公司暂时未履
                              11,036.07            2,099.47      425.66%  行交付药品义务所
                                                                          致。

                                                                          因销售规模增加,期
应交税费                      6,648.09            4,181.30      59.00%  末应缴纳的各项税费
                                                                          增加所致。

其他应付款                                                                主要是购买非流动资
                              31,440.97          18,499.41      69.96%  产待付款增加所致。

其他流动负债                  1,421.69              258
[点击查看PDF原文]